Serina Therapeutics
Update in progressSER (NYSE American)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Serina Therapeutics, Inc. is a Huntsville, Alabama–based biotechnology company developing drugs for neurological diseases and pain. Its lead candidate, SER 252 (POZ-apomorphine), is a POZ-conjugate in phase 1 for advanced Parkinson’s disease. It also develops POZ-lipids as non-immunogenic alternatives to PEG-lipids for lipid nanoparticles. SER 214 (POZ-rotigotine) targets early Parkinson’s and Restless Legs Syndrome and has completed phase 1a. The firm also pursues POZ RNA vaccine tech.
Company score
- Sentiment
- 0.28
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.00
- Governance
- 0.00
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.00
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.14
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNYSE American (ASE)
- LocationUnited States
- CEOMr. Steven A. Ledger
- Founded2006
- Employees16
- Websiteserinatherapeutics.com
Identifiers
- ISINUS81751A1088
- FIGIBBG00HCXQ7B0
- CUSIP81751A108
- CIK0001708599